Rob Dillard

DocwireNews

The diagnosis of AL amyloidosis requires a high index of suspicion to render a prompt diagnosis and appropriate treatment, according to a case study which was presented at AHA 2024.
The case involved a 62-year old man with a history of chronic kidney disease and paroxysmal atrial fibrillation. The patient presented with several months of fatigue, a progressive decline in functional status, as well as weight loss, and intermittent lower extremity swelling. His blood pressure was 92/72 mmHg on presentation, and heart rate was 90 bpm. Upon physical examination, the patient had a jugular venous pressure of 12-14 cm H2O and 2+ bilateral lower extremity edema with mild wheezing.
The results of laboratory tests showed that the patient had a significant serum free light chain ratio of 0.14. A transthoracic echocardiogram revealed a left ventricular (LV) ejection fraction of 33% with increased LV wall thickness and severe bi-atrial enlargement. The patient&#8217;s bone marrow biopsy revealed 2% lambda restricted plasma cells without evidence of amyloid deposits, and a metastatic bone survey was negative. Also, a fat pad biopsy and endomyocardial biopsy both stained negative for amyloid. However, a cardiac MRI revealed diffuse, circumferential subendocardial late gadolinium enhancement, which is consistent with cardiac amyloidosis. The patient was also given chest CT scan which showed a few patchy nodular pulmonary infiltrates. Due to the negative results, he was referred to pulmonary and endobronchial biopsy was positive for amyloid on Congo red staining. Biopsy tissue typing ultimately led to the diagnosis of Lambda subtype AL amyloidosis.
The patient was initiated on daratumumab, cyclophosphamide, bortezomib, and dexamethasone treatment. Unfortunately, approximately month after his diagnosis, he developed worsening heart failure despite treatment. Subsequently, he was admitted to an outside hospital with refractory cardiogenic shock and died.
&#8220;An expedited, multimodal and interdisciplinary diagnostic assessment is imperative as prognosis with chemotherapy is highly dependent on extent of AL disease, patient functional status, and presence of cardiac compromise. Elevated natriuretic peptides, troponins, autonomic dysfunction, and hypotension are negative prognostic features,&#8221; the researchers concluded.
Reference
Zimmerman A, Kuriakose P, Godfrey A, Ananthasubramaniam K, Cowger J, Al-Darzi W. A diagnostic challenge overcome with persistent clinical suspicion in a case of cardiac AL amyloidosis. Abstract #Mo2081. Presented at the American Heart Association Scientific Sessions 2024; November 16-18, Chicago, Illinois.

Case Study: Wild-Type Transthyretin Cardiac Amyloidosis in the Setting of Familial Hypertrophic Obstructive Cardiomyopathy

AHA 2024: CardioNerds

Case Study Highlights the Challenge of Accurately Diagnosing Cardiac AL Amyloidosis

Cecilia Brown

US Surgeon General Releases New Report on Tobacco-Related Disease, Death, and Disparities

Lung Cancer

Latest News

The diagnosis of AL amyloidosis requires a high index of suspicion to render a prompt diagnosis and appropriate treatment.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe